Enhanced Games shocked expectations when a lone swimmer unlocked the million-dollar bonus while several clean athletes outperformed enhanced rivals, deepening the dispute over drugs in sport
The Enhanced Games landed at Resorts World Las Vegas as a deliberately provocative experiment: an athletic showcase where competitors could use certain FDA-approved drugs that are banned in mainstream sport. Promoters argued that allowing supervised use of substances would produce staggering performances and rewrite record books.
Instead, the event produced a more nuanced outcome in which enhanced competitors, clean athletes and strict medical protocols combined to create both spectacle and controversy.
Held in a custom-built 2,500-seat arena, the meeting featured a compact programme of sprints, swimming and strength tests.
Organisers promised generous financial rewards and upgraded medical oversight via an IRB trial, yet critics from established federations warned of safety risks and damage to sport’s integrity. The result was an evening that answered some questions while opening many more — notably about whether pharmacological enhancement is a shortcut to guaranteed world records.
What happened in Las Vegas
The headline moment came in the men’s 50m freestyle when Greek sprinter Kristian Gkolomeev touched in 20.81 seconds, a mark that organisers celebrated as faster than the official benchmark and therefore worthy of the $1,000,000 jackpot. Gkolomeev’s performance was aided by the event’s supervised medical protocols and by wearing a high-buoyancy bodysuit that is banned in conventional competition. Despite that singular victory, the remainder of the card saw few definitive record-breaking feats: several enhanced athletes approached historic times but fell short, and some clean competitors outshone those who took drugs.
Standout performances and near-misses
Notable near-misses included Britain’s Ben Proud, who swam the 50m butterfly in 22.32 seconds — just 0.05 seconds off the all-time mark — and American Cody Miller, who produced a personal-best 26.55 in the 50m breaststroke after an intense eight-week enhancement cycle but remained behind the world standard. On the other side, unenhanced entrants produced headline-grabbing results: Hunter Armstrong declined the event’s protocols and still won the 50m backstroke in 24.21 seconds, leaving enhanced rivals behind, while Fred Kerley ran 9.93 in a heat and 9.97 to win the 100m final as a self-declared non-enhanced athlete. Strongman lifts that many expected to challenge records did not produce new benchmarks either; both Mitchell Hooper and Thor Björnsson failed to top the existing deadlift mark.
Rules, prizes and medical oversight
The organisers set out a clear, if contentious, framework: athletes could take substances that have passed the United States FDA approval process — including testosterone, anabolic agents such as methenolone and nandrolone, hormones like human growth hormone and EPO, and metabolic modulators such as meldonium — under supervised conditions. According to the event, 37 of 42 competitors participated in an IRB trial in Abu Dhabi that monitored health metrics from cardiovascular scans to blood and urine analysis. The prize structure was also notable: a $500,000 event pool with $250,000 to the winner, a $250,000 bonus for beating an official world record, and a $1,000,000 jackpot for two glamour events — the 50m freestyle and the 100m sprint. The show ran alongside a live-stream deal on Roku in the US and international coverage on YouTube, capped by a post-event concert by The Killers.
Who chose not to enhance and who did
Not every competitor accepted the pharmacological offer. High-profile names such as Hunter Armstrong and Tristan Evelyn competed without enhancements to protect Olympic eligibility, while others underwent private supervised protocols outside the Abu Dhabi trial. The organisers also disclosed appearance fees and annual salaries that in some cases exceeded what athletes received from national federations, a financial incentive that has complicated the ethical and sporting conversation around the event.
The debate beyond the arena
International anti-doping bodies and federation leaders reacted angrily. WADA called the concept “dangerous and irresponsible,” warning of long-term health consequences from prohibited substances, and senior figures such as Sebastian Coe and Travis Tygart dismissed the spectacle in blunt terms. Organisers defend the event as a laboratory for medical monitoring and as a commercial platform to sell high-quality supplements and anti-ageing products, arguing that transparency and clinical oversight are preferable to covert cheating. Yet the Las Vegas results — a single million-dollar record and several clean athletes outperforming enhanced rivals — make it harder to claim that drugs are an automatic route to rewriting elite sport.
For athletes, fans and regulators the Enhanced Games has returned the debate to first principles: what constitutes fairness, what health standards are acceptable for entertainment, and whether admitting pharmacology into competition creates useful scientific data or merely a commercialised, risky alternative to traditional sport. The Las Vegas experiment has not resolved those questions; instead, it has sharpened them, ensuring the conversation will continue across locker rooms, laboratory reports and governing bodies.
